
Lakefront sells early-stage CAR-T cell therapy programs to Armed Cell Therapeutics for up to $230M plus royalties
Lakefront Biotherapeutics has completed the sale of its preclinical CAR-T cell therapy programs to Belgium-based Armed Cell Therapeutics. The deal includes an upfront payment of €8 million, potential milestone payments up to $230 million, and a low s...





